ARCA BIOPHARMA UPDATES SPECIAL PROTOCOL ASSESSMENT REQUEST TO FDA FOR GENCARO PHASE 3 ATRIAL FIBRILLATION CLINICAL TRIAL Posted on December 20, 2018 by ARCA IT - Press Release, Uncategorized Gencaro Phase 3 FDA SPA Amendment- FINAL